Max Healthcare Share Price

Founded in 2001, Max Healthcare Institute Limited (MHIL) is one of the largest hospital chains in India in terms of income from healthcare services, as of FY 2023. The company is also engaged in medical education and training.

Max Healthcare Institute Limited has a significant presence in North India with 17 of its hospitals and medical institutes operating in the region. Out of the whole network, eight hospitals and four medical centers are located in Delhi and the NCR; the other centres are in Mumbai, Mohali, Bathinda and Dehradun.

As of FY23, MHIL provides medical care facilities in over 550 cities across India. The company is primarily focused on the metro cities.

The company went public in August 2020. The company is listed both on BSE Limited and National Stock Exchange (NSE). The company became a public entity after the healthcare business of Radiant Life was demerged into Max Healthcare and the former Max India was merged into the parent company. In June 2019, Radiant Life had already purchased a 49.7% stake in Max Healthcare.

The market capitalisation of Max Healthcare Limited stood at over ₹76,700 crore, as of February 5, 2024. Max Healthcare share price has surged more than 340% in the last three years.

Max Healthcare business operations

The Max Healthcare network includes hospitals and clinics run by its affiliates, in addition to partner and managed healthcare facilities.

These include state-of-the-art tertiary and quaternary care hospitals at Saket, Patparganj, Vaishali, Rajendra Place, and Shalimar Bagh in Delhi- NCR; a secondary care hospital in Gurgaon; and day care centers in Noida, Lajpat Nagar and Panchsheel Park.

In addition to running its primary hospital, MHIL also runs Max@Home and Max Lab, two SBUs. Max@Home is a platform that provides health and wellness services at home, while Max Lab provides diagnostic services to patients outside its network.

Apart from patient care, the hospital chain is also engaged in medical research and innovation through its dedicated research centres. The research centres have pursued innovations in the fields of metabolic diseases, oncology, cardiology, neurology and public health. Over the last seven years, Max Healthcare has produced approximately 2,000 research papers, published in reputed medical journals across the globe. The hospital chain has also formed alliances with IIT Bombay, Ashoka University and IIIT Delhi as well as Imperial College London and Royal Melbourne Institute of Technology, Australia, for clinical research in diverse areas.

Max Healthcare Institute Limited has also launched a two-year Masters of Public Health Programme and a PhD programme in various scientific disciplines in collaboration with AcSIR. The company has also started an Advanced Trauma Life Support (ATLS) programme with American College of Surgeons.

Financial highlights

• The company’s consolidated revenue from operations stood at ₹4,562.60 crore in FY23 as against ₹3,936.55 crore in FY22.
• In FY23, the company’s net profit increased to ₹1,103 crore as against ₹608 crore in FY22.
• Its EBITDA (earnings before interest, tax, depreciation and amortisation) stood at ₹1,380 crore in FY23 as against ₹1,070 crore in FY22.
• The EBITDA margin improved to 29.3% in FY23 compared to 26.4% in FY22.
• Its earnings per share (EPS) stood at ₹11.38 in FY23 compared to ₹6.25 in FY22.

12 September 2025 – Max Healthcare Share Price Update

As of last trading day, Max Healthcare opened at ₹1,168.50 and last traded at ₹1,179.30, showing a fall of 1.40 points (0.12%) compared to the previous close of ₹1,180.70. During the session, the stock touched a high of ₹1,181.00 and a low of ₹1,168.00. The company's market capitalization now stands at ₹1,14,792 Crs, with a P/E ratio of 100.6 and a dividend yield of 0.14%.